Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day. PD-1 inhibitor Keytruda (pembrolizumab) has been approved as a second-line therapy for head and n...
Original Article: Merck claims a brace of head and neck cancer approvals